https://www.live-feeds.com/feed/how-cardiologists-high-hopes-for-two-drugs-were-dashedContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/how-cardiologists-high-hopes-for-two-drugs-were-dashedhttps://www.live-feeds.com/feed/how-cardiologists-high-hopes-for-two-drugs-were-dashed#u192232Tue, 10 Nov 2026 22:15:45 +0000Novartis announced that its Phase 3 HORIZON trial of pelacarsen failed to reduce major cardiovascular events even though the drug successfully lowered lipoprotein(a) levels. The Cleveland Clinic-led study tested the antisense oligonucleotide in patients with elevated Lp(a) and established cardiovascular disease. Results stunned cardiologists who had viewed Lp(a) reduction as a promising therapeutic target. The failure casts doubt on similar programs in development at Amgen and Eli Lilly. Pelacarsen had been considered a potential breakthrough for an inherited risk factor affecting roughly one